- Trial phase
- Approved (marketed); new Phase 3 label-expansion trial (SIGMA) just begun enrolling
- Time to market
- Already on the market (approved and commercialized). Label expansion into secondary immunodeficiency is estimated years away, readouts likely 2-3 years out per company commentary.
- Why 4/10
- Gamunex-C is already FDA-approved and marketed, and the only pending hard catalyst tied to it, the Phase 3 SIGMA topline readout for a secondary-immunodeficiency label expansion, is years away (first patients were dosed only in July 2026, with readouts estimated 2-3 years out), so there is no dated binary for this drug in the next ~12 months; per the rubric an approved drug with no pending regulatory decision caps at 3-5, and 4 reflects it being Grifols' flagship franchise.
For Grifols (GRFS), Gamunex-C is a core revenue asset but not a near-term stock catalyst, the share-price drivers in the next ~12 months are company-wide (SPARTA Prolastin-C topline expected by end-2026, quarterly results), not Gamunex-C-specific. Watch SIGMA/XPERT enrollment updates for optionality, but treat the label-expansion payoff as a 2028+ event. Note the tape is mixed: positive analyst consensus and Q2 2026 13F accumulation by several managers, but also high short-volume flow and multiple 13F trims/exits.
Price Chart
Executive Summary
GAMUNEX-C (immune globulin intravenous, human, IGIV-C) is Grifols' flagship FDA-approved intravenous immunoglobulin, already a commercial product; the defining approval binary long since passed. The relevant news is that in July 2026 Grifols dosed the first patients in two Phase 3 trials (SIGMA for GAMUNEX-C in secondary immunodeficiency, XPERT for its SCIg sibling XEMBIFY) to expand U.S. labels, a large (>1M U.S. patients) but years-away opportunity. Grifols' analyst consensus is mostly positive (9 Buy + 5 Strong Buy vs 2 Sell) and the mean price target of ~$10.87 implies ~40% upside from ~$7.75, though the target sample is just 2 analysts; Q2 2026 13F data is mixed (accumulation from BofA/Norges/Citadel, trims from JPMorgan/UBS/FMR/BMO).
How It Works
Gamunex-C is a concentrated solution of antibodies (immunoglobulins) purified from human blood plasma, given by IV infusion. It bolsters or replaces a patient's own immune defenses, used to treat people whose immune systems don't make enough antibodies (primary and secondary immunodeficiency) and certain autoimmune/nerve conditions where antibodies dampen the immune attack (e.g., CIDP, ITP). The July 2026 Phase 3 program aims to add a label indication for cancer patients whose immune systems are weakened by their disease or treatment.
Trial Status
Gamunex-C is an approved IVIg used in immune deficiency and neuro conditions (it is the active comparator in Grifols' XPERT CIDP non-inferiority trial). In July 2026 Grifols dosed the first patients in the Phase 3 SIGMA trial seeking a U.S. label expansion into secondary immunodeficiency in blood cancers (CLL, MM, NHL, a population of >1 million U.S. patients); it is an open-label, multicenter study with a reported ~50-patient sample. No efficacy data released; readout years out.
The Two-Sided Case
Upcoming Catalysts
- SPARTA Phase 3 (Prolastin-C, a different Grifols drug): clinical portion completed Aug 2026; topline results expected by end of 2026, the nearest dated company catalyst, but not Gamunex-C.
- SIGMA (Gamunex-C SID) and XPERT (XEMBIFY CIDP) Phase 3 enrollment updates, no dated readout yet; likely 2-3 years out.
- Grifols quarterly results and SEC 6-K/20-F filings (20-F filed 2026-04-17; periodic 6-Ks).
- Analyst actions / price-target updates (consensus refreshed Aug 2026) and 13F disclosures for Q3 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Grifols, S.A. Press Release GRFS ·Originating report